Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer
Phase 3
Recruiting
- Conditions
- Pancreatic Neoplasms
- Interventions
- Drug: QingyiHuaji optimized formula
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 306
- Registration Number
- NCT05840341
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Pyrotinib Plus Trastuzumab and Chemotherapy in HER2+ Metastatic Breast Cancer Patients
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 161
- Registration Number
- NCT05839288
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
Phase 1
Recruiting
- Conditions
- High-Risk Localized Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05839275
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)
Phase 2
Recruiting
- Conditions
- Advanced Intrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05835245
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)
Phase 2
Recruiting
- Conditions
- Advanced Biliary Tract Cancer
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT05823987
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）
Phase 1
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: SHR-A1811Drug: TROP2 ADC
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 56
- Registration Number
- NCT05824325
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
Phase 2
Not yet recruiting
- Conditions
- Recurrent Ovarian Cancer
- Interventions
- Drug: Fuzuloparib Combination with Bevacizumab
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT05819060
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Cente, Shanghai, Shanghai, China
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Phase 3
Recruiting
- Conditions
- Triple-Negative Breast Cancer
- Interventions
- Drug: Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1Drug: VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabineDrug: nab-paclitaxel, with maintenance of capecitabineDrug: VEGFR and TPC
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 192
- Registration Number
- NCT05806060
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
Phase 2
Not yet recruiting
- Conditions
- Hormone Receptor-positive Advanced Breast Cancer
- Interventions
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 23
- Registration Number
- NCT05806047
Negative ER Expression Assessed by 18F-FES PET/CT in the MBC With ER-positive Primary Tumor
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05797987
- Locations
- 🇨🇳
Biyun Wang, MD, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath